{
    "wpid": "WP5496",
    "organisms": ["Homo sapiens"],
    "description": "\"Trastuzumab and pertuzumab inhibit HER2 signaling by binding to the extracellular domain of HER2. Lapatinib, neratinib, tucatinib, and pyrotinib inhibit HER signaling by binding to the intracellular tyrosine kinase domain of the Her family members. EGFR epidermal growth factor receptor, HER human epidermal growth factor receptor, MEK MAP kinase kinase, ERK MAP kinase, PI3K phosphoinositide 3-kinases (adapted from \u201cHER2 Signaling Pathway\u201d, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates)\".  Source: Figure F1, https://pmc.ncbi.nlm.nih.gov/articles/PMC9281252/.  Derived from PFOCR, https://pfocr.wikipathways.org/figures/PMC9281252__12032_2022_1749_Fig1_HTML.html.",
    "ontology-ids": [
        "CL:0002327",
        "PW:0000754",
        "CL:0002326",
        "DOID:1612",
        "PW:0000624"
    ],
    "last-edited": "2024-11-12",
    "title": "Targeted therapy in breast cancer",
    "authors": ["Eweitz"],
    "revision": "r135813"
}